Skip to main content
. 2015 Apr 2;10(4):e0119950. doi: 10.1371/journal.pone.0119950

Fig 3. Courses of donor chimerism after MHC class II disparate BMT in recipients conditioned by 6 Gy of TBI and treated with immunosuppression.

Fig 3

LEW.1AR2 male rats were irradiated with 6 Gy of TBI and received 1 x 108 BMC from LEW.1AR1 donor rats one day after TBI. Recipients were additionally treated either with sirolimus (Srl) or cyclosporine A (CsA). Control animals did not receive any immunosuppression (no IS). Donor chimerism was detected within blood B cells by flow cytometry using donor-specific anti-RT1B/Du mAb (1H1A) on days 14, 30, 60 and 100 post BMT. (A) Mean values of chimerism from groups receiving Srl for 14 days (Srl 14d; n = 13) or CsA for 14 days (CsA 14d; n = 11) as well as control animals (no IS; n = 11). (B) Mean values of chimerism from groups receiving Srl for 28 days (Srl 28d; n = 15) or CsA for 28 days (CsA 28d; n = 10). The statistical significance was appointed at * p < 0.05 for BMT groups receiving immunosuppression for 14 days and TBI alone (A) as well as for both groups receiving immunosuppression for 28 (B).